论文部分内容阅读
目的 探讨不规范停用恩替卡韦慢性乙型肝炎复发后再次使用恩替卡韦治疗的效果.方法 选取2017年2月至2018年2月100例不规范停用恩替卡韦后复发的慢性乙型肝炎患者作为研究组,另选取同期100例初治慢性乙型肝炎患者作为对照组.两组均予以恩替卡韦抗病毒治疗,连续治疗24周,记录两组临床疗效、药物相关不良反应发生情况.结果 研究组用药12、24周乙型肝炎病毒DNA转阴率 (54.00％、68.00％) 与对照组 (57.00％、70.00％) 比较,差异未见统计学意义 (P＞0.05);治疗期间两组慢性乙型肝炎患者药物相关不良反应发生率比较,差异未见统计学意义 (P＞0.05).结论 应用恩替卡韦治疗后不规范停药的慢性乙型肝炎患者复发时再次经恩替卡韦治疗有效性、安全性均较优.“,”Objective To investigate the efficacy of entecavir on recurrent chronic hepatitis B patients after nonstandard discontinuation of entecavir. Methods A total of 100 patients with chronic hepatitis B who relapsed after nonstandard withdrawal of entecavir from February 2017 to February 2018 were selected as the study group. Another 100 cases of chronic hepatitis B during the same period were selected as control group. Two groups were treated with entecavir antiviral therapy. Continuous treatment for 24 weeks. The clinical efficacy and adverse drug reactions of the two groups were recorded. Results HBV DNA negative rate (54.00％, 68.00％) in study group and control group (57.00％, 70.00％) at 12 and 24 weeks after treatment, the difference was not significant (P＞0.05) .The incidence of drug related adverse reactions in two groups of patients with chronic hepatitis B during treatment was compared, the difference was not significant (P＞0.05) .Conclusions The efficacy and safety of entecavir in patients with chronic hepatitis B who are not standardized after entecavir treatment is better.